Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RZJIL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Tamrintamab pamozirine
|
|||||
| Synonyms |
tamrintamab pamozirine; SC-003; DC-1728001
Click to Show/Hide
|
|||||
| Organization |
Stemcentrx (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Tamrintamab
|
Antibody Info | ||||
| Antigen Name |
Dipeptidase 3 (DPEP3)
|
Antigen Info | ||||
| Payload Name |
SG3199 (SC-DR002)
|
Payload Info | ||||
| Therapeutic Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala-PABC
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
pamozirine
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Ovarian cancer |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Partial Response (PR) |
1.72%
|
|||
| Patients Enrolled |
Female patients (age 18 years) with EOC if they had evidence of progressive disease during or within 6 months of receiving a platinum regimen.
|
||||
| Administration Dosage |
1 of 6 dose levels (0.025-0.40 mg/kg) every 3 weeks (Q3W), utilizing a standard 3+3 design (dose-limiting toxicity [DLT] period: 21 days).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02539719 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1a/1b dose escalation and expansion study of SC-003 as a single-agent and in combination with ABBV-181 in subjects with platinum-resistant/ refractory ovarian cancer. | ||||
| Primary Endpoint |
The MTD for the Q3W schedule was 0.30 mg/kg and the SC-003 doses selected for the dose-expansion phase of the study were 0.30 mg/kg and 0.20 mg/kg.
|
||||
| Other Endpoint |
ORR=5.17% (N=3/58), 3 patients achieved PR. All responses were observed at 0.20-0.30mg/kg. Responses were not durable, with only 1 PR confirmed on the follow-up 16-week scan.
|
||||
References